EPO / erythropoiesis-stimulating agents (ESAs)
Muscle & Strength · Erythropoietin receptor agonist
Tier C+
High-risk evidence profile
Bottom line
Read Off Label grades EPO / erythropoiesis-stimulating agents (ESAs) as C+ (5.6/10) based on strong evidence, high benefit magnitude, and a high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 2/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
WADA coverage: erythropoietins/EPO, darbepoetins/dEPO, EPO-based constructs, EPO-Fc, methoxy polyethylene glycol-epoetin beta/CERA, EPO-mimetic agents and constructs, CNTO-530, peginesatide and pegmolesatide.
Studied, labeled, or reported-use context: Clinical anemia dosing is individualized by hemoglobin response; no safe performance dose — Rx for anemia indications; WADA S2 prohibited at all times; not individualized guidance.
What the evidence says
WADA coverage: erythropoietins/EPO, darbepoetins/dEPO, EPO-based constructs, EPO-Fc, methoxy polyethylene glycol-epoetin beta/CERA, EPO-mimetic agents and constructs, CNTO-530, peginesatide and pegmolesatide. Additional WADA alias coverage: EPO-mimetic agents and their constructs, Asialo EPO and Carbamylated EPO (CEPO).
Mechanism
EPO receptor agonists increase red-cell mass and oxygen-carrying capacity, which can improve endurance but also increases blood viscosity and thrombotic risk.
Studied, labeled, or reported dose & route
Clinical anemia dosing is individualized by hemoglobin response; no safe performance dose
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about EPO / erythropoiesis-stimulating agents (ESAs)'s effects?
- Read Off Label rates the evidence for EPO / erythropoiesis-stimulating agents (ESAs) as Strong and the benefit magnitude as high, producing an overall grade of C+ (5.6/10). WADA coverage: erythropoietins/EPO, darbepoetins/dEPO, EPO-based constructs, EPO-Fc, methoxy polyethylene glycol-epoetin beta/CERA, EPO-mimetic agents and constructs, CNTO-530, peginesatide and pegmolesatide.
- What safety findings are reported for EPO / erythropoiesis-stimulating agents (ESAs)?
- EPO / erythropoiesis-stimulating agents (ESAs) has a high risk profile in the database. High (hypertension, thrombosis, stroke, polycythemia, pure red-cell aplasia with some products) Legal status: Rx for anemia indications; WADA S2 prohibited at all times.
- What does the low Safety score for EPO / erythropoiesis-stimulating agents (ESAs) represent?
- The Safety score is 2/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for EPO / erythropoiesis-stimulating agents (ESAs)?
- Clinical anemia dosing is individualized by hemoglobin response; no safe performance dose This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does EPO / erythropoiesis-stimulating agents (ESAs) work?
- EPO receptor agonists increase red-cell mass and oxygen-carrying capacity, which can improve endurance but also increases blood viscosity and thrombotic risk.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.